Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
CytoReason
company
About
CytoReason develops a cell-centered computational model of the human body designed to discover complex patterns in biological data.
- 51 - 100
Highlights
Details
- Last Funding Type
- Series A
- Industries
- Biopharma,Biotechnology,Health Care,Health Diagnostics,Pharmaceutical
- Founded date
- Sep 1, 2016
- Number Of Employee
- 51 - 100
- Operating Status
- Active
CytoReason develops a cell-centered computational model of the human body designed to discover complex patterns in biological data. The company collects proprietary data from pharma companies and uses it to simulate human diseases tissue by tissue, cell by cell. With CytoReason’s massive database and AI-led platform, pharma and biotech companies identify new opportunities, shorten trial phases, reduce development costs and increase the likelihood of approval.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$20M
CytoReason has raised a total of
$20M
in funding over 2 rounds. Their latest funding was raised on
Sep 20, 2022 from a Corporate Round round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 20, 2022 | Corporate Round | $20M | 1 |
Pfizer
|
— | Detail |
| Jun 9, 2021 | Series A | — | 1 | — | — | Detail |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
